Search results
Results from the WOW.Com Content Network
The US label for sodium oxybate has a black box warning because it is a central nervous system depressant (CNS depressant) and for its potential for abuse.Other potential adverse side effects include respiratory depression, seizures, coma, and death, especially when it is taken in combination with other CNS depressants such as alcohol.
Sodium phenylbutyrate is taken orally or by nasogastric intubation as a tablet or powder, and tastes very salty and bitter. It treats urea cycle disorders, genetic diseases in which nitrogen waste builds up in the blood plasma as ammonia glutamine (a state called hyperammonemia) due to deficiences in the enzymes carbamoyl phosphate synthetase I, ornithine transcarbamylase, or argininosuccinic ...
Bupropion, when used for treating long-term weight gain over six to twelve months, results in an average weight loss of 2.7 kilograms (6.0 lb) over placebo. [74] This is not much different from the weight loss produced by several other weight-loss medications such as sibutramine or orlistat . [ 74 ]
Sodium butyrate is a compound with formula Na(C 3 H 7 COO). It is the sodium salt of butyric acid. It has various effects on cultured mammalian cells including inhibition of proliferation, induction of differentiation and induction or repression of gene expression. [1] As such, it can be used in lab to bring about any of these effects.
What links here; Related changes; Upload file; Special pages; Permanent link; Page information; Cite this page; Get shortened URL; Download QR code
Overall, our findings suggest that more people over 70 years of age should be considered for statin treatment.” — Borislava Mihaylova, DPhil “Cardiovascular disease remains a leading cause ...
Among adults 60 or older, nearly 30% reported taking aspirin to prevent cardiovascular disease, and around 5% of all adults 60 or older reported using aspirin without medical advice.
In March 2024, Amylyx Pharmaceuticals announced that its Phase III PHOENIX clinical trial of 664 American and European adults followed over 48 weeks showed no statistically significant difference in the functioning of ALS patients that were randomly assigned to treatment with Relyvrio, as compared to those receiving a placebo drug.